ZA932641B - Methods and compositions for the treatment of diseases with interferon while reducing side effects - Google Patents

Methods and compositions for the treatment of diseases with interferon while reducing side effects

Info

Publication number
ZA932641B
ZA932641B ZA932641A ZA932641A ZA932641B ZA 932641 B ZA932641 B ZA 932641B ZA 932641 A ZA932641 A ZA 932641A ZA 932641 A ZA932641 A ZA 932641A ZA 932641 B ZA932641 B ZA 932641B
Authority
ZA
South Africa
Prior art keywords
interferon
treatment
methods
side effects
compositions
Prior art date
Application number
ZA932641A
Other languages
English (en)
Inventor
Lawrence M Blatt
Milton W Taylor
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25352556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA932641(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA932641B publication Critical patent/ZA932641B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA932641A 1992-04-15 1993-04-15 Methods and compositions for the treatment of diseases with interferon while reducing side effects ZA932641B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/868,916 US5372808A (en) 1990-10-17 1992-04-15 Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Publications (1)

Publication Number Publication Date
ZA932641B true ZA932641B (en) 1993-10-22

Family

ID=25352556

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932641A ZA932641B (en) 1992-04-15 1993-04-15 Methods and compositions for the treatment of diseases with interferon while reducing side effects

Country Status (26)

Country Link
US (1) US5372808A (Direct)
EP (3) EP1419782A1 (Direct)
JP (2) JPH07505894A (Direct)
KR (1) KR950701350A (Direct)
CN (1) CN1098103C (Direct)
AT (1) ATE254926T1 (Direct)
AU (1) AU683214B2 (Direct)
CA (1) CA2118121C (Direct)
CZ (1) CZ247194A3 (Direct)
DE (1) DE69333321T3 (Direct)
DK (1) DK0911033T4 (Direct)
ES (1) ES2210864T5 (Direct)
HU (1) HU227310B1 (Direct)
IL (1) IL105366A (Direct)
MX (1) MX9302160A (Direct)
NO (1) NO318643B1 (Direct)
NZ (1) NZ252871A (Direct)
PT (1) PT911033E (Direct)
RO (1) RO115700B1 (Direct)
RU (1) RU2128056C1 (Direct)
SG (1) SG52443A1 (Direct)
SK (1) SK284712B6 (Direct)
TW (1) TW265265B (Direct)
UA (1) UA44223C2 (Direct)
WO (1) WO1993021229A1 (Direct)
ZA (1) ZA932641B (Direct)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
PL176408B1 (pl) * 1992-02-10 1999-05-31 Interferon Sciences Inc Kompozycja naturalnego alfa interferonu z ludzkich leukocytów krwi obwodowej i sposób wytwarzania kompozycji naturalnego alfa interferonu z ludzkich leukocytów krwi obwodowej
US6001589A (en) * 1993-06-11 1999-12-14 Pbl Biomedical Laboratories, Inc. Method of identifying proteins modified by disease states related thereto
CA2164811A1 (en) 1993-06-11 1994-12-22 Sidney Pestka Super proteins including interferons and interleukins
AU1299295A (en) * 1993-12-02 1995-06-19 President And Fellows Of Harvard College Improved efficacy of alpha-helical cytokines
DK0726778T3 (da) * 1994-02-08 2001-09-24 Amgen Inc Oral administration af kemisk modificerede proteiner
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL116730A0 (en) * 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
DE69636112T2 (de) * 1995-08-30 2006-12-14 Toray Industries, Inc. Verfahren zum testen von myocarditis und cardiomyopathie
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5831062A (en) * 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
DE69735202T2 (de) * 1996-05-09 2006-11-02 Pharma Pacific Pty. Ltd., Brighton-Le-Sands Stimulierung wirtseigener abwehrmechanismen gegen krebs
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
WO2000018427A1 (en) * 1998-09-29 2000-04-06 Fleischmann W Robert Methods of treating diseased cells
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
RU2140285C1 (ru) 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
IL144361A0 (en) * 1999-01-29 2002-05-23 Hoffmann La Roche Gcsf conjugates
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
US20020151525A1 (en) 2000-10-25 2002-10-17 Collins Douglas A. Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2179000C1 (ru) * 2000-12-21 2002-02-10 Тверская государственная медицинская академия Способ комплексного лечения базалиом кожи
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
EP1435997A4 (en) * 2001-09-28 2006-03-01 Intermune Inc TECHNIQUE FOR TREATING HEPATITIS C VIRUS INFECTION FOR PATIENTS WHOSE TREATMENT FAILED
WO2003026674A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
WO2003030923A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
CA2472588A1 (en) * 2002-01-16 2003-07-31 Pepgen Corporation Oral administration of interferon-tau
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
KR20050048544A (ko) 2002-06-28 2005-05-24 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용의 변형된 2' 및3'-뉴클레오사이드 프로드럭
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
LT2604620T (lt) 2003-05-30 2016-09-12 Gilead Pharmasset Llc Modifikuoti fluorintų nukleozidų analogai
ES2351603T3 (es) 2003-07-25 2011-02-08 Idenix Pharmaceuticals, Inc. Análogos de nucleósidos de purina para el tratamiento de enfermedades causadas por flaviridae incluyendo hepatitis c.
SI2325202T1 (sl) * 2003-08-28 2015-02-27 Superlab Far East Limited Uporabe interferonov s spremenjeno prostorsko strukturo
EP1670817A4 (en) 2003-08-28 2008-07-16 Huiyangtech Usa Inc USE OF A SPATIAL CONFIGURATION FOR MODULATING A PROTEIN FUNCTION
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
JP4584260B2 (ja) 2003-10-14 2010-11-17 インターミューン・インコーポレーテッド Ｈｃｖ複製阻害剤としての大環状カルボン酸およびアシルスルホンアミド
PT1706403E (pt) * 2003-12-22 2012-04-23 Gilead Sciences Inc Compostos de imidazo[4,5-c]piridina e métodos de tratamento antiviral
EP1711159B1 (en) 2003-12-30 2013-03-20 Durect Corporation Solid implants containing a block copolymer for controlled release of a gnrh compound
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
JP2008507298A (ja) 2004-05-19 2008-03-13 マキシジェン， インコーポレイテッド インターフェロンαポリペプチドおよび結合体
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SG158136A1 (en) 2004-09-14 2010-01-29 Pharmasset Inc Preparation of 2`-fluoro-2`- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
CN101137391B (zh) * 2005-03-09 2012-07-18 魏光文 重组高效复合干扰素的用途
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
WO2007044083A2 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
NZ594105A (en) 2005-07-25 2013-02-22 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
CA2624333A1 (en) 2005-10-11 2007-04-19 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
CA2634749C (en) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ617066A (en) * 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
WO2010075549A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
JP5908397B2 (ja) * 2009-06-09 2016-04-26 デフィルス、インコーポレイテッドＤｅｆｙｒｕｓ， Ｉｎｃ． 病原体感染を予防又は治療するためのインターフェロン投与
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
ES2516466T3 (es) 2010-03-31 2014-10-30 Gilead Pharmasset Llc Síntesis estereoselectiva de agentes activos que contienen fósforo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
EP3305315A1 (en) 2010-09-28 2018-04-11 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8302778A1 (es) † 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
SE8502430L (sv) † 1985-05-15 1986-11-16 Kabivitrum Ab En cdna-molekyl som kodar for expressionen av en polypeptid av typen interferon alfa, en bakteriell eller celluler verd transformerad med en sadan molekyl och en polypeptid som uppvisar interferonaktivetet framstelld me
DE3685996T2 (de) † 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders

Also Published As

Publication number Publication date
TW265265B (Direct) 1995-12-11
DE69333321T3 (de) 2010-03-18
NO318643B1 (no) 2005-04-25
NO943901D0 (no) 1994-10-14
DK0911033T4 (da) 2010-03-22
UA44223C2 (uk) 2002-02-15
JPH07505894A (ja) 1995-06-29
PT911033E (pt) 2004-04-30
CN1098103C (zh) 2003-01-08
EP1419782A1 (en) 2004-05-19
ATE254926T1 (de) 2003-12-15
EP0641359A1 (en) 1995-03-08
DE69333321D1 (de) 2004-01-08
CZ247194A3 (en) 1995-04-12
IL105366A0 (en) 1993-08-18
EP0911033A3 (en) 1999-05-19
JP2005029561A (ja) 2005-02-03
RO115700B1 (ro) 2000-05-30
HK1018595A1 (en) 1999-12-30
KR950701350A (ko) 1995-03-23
HU227310B1 (en) 2011-03-28
RU2128056C1 (ru) 1999-03-27
CA2118121A1 (en) 1993-10-28
HUT70216A (en) 1995-09-28
IL105366A (en) 1999-11-30
ES2210864T5 (es) 2010-03-09
SK124794A3 (en) 1995-04-12
SK284712B6 (sk) 2005-09-08
EP0911033A2 (en) 1999-04-28
HU9402979D0 (en) 1995-02-28
WO1993021229A1 (en) 1993-10-28
ES2210864T3 (es) 2004-07-01
DE69333321T2 (de) 2004-09-16
CA2118121C (en) 2005-08-02
EP0641359A4 (en) 1995-10-04
EP0911033B1 (en) 2003-11-26
NZ252871A (en) 1997-08-22
SG52443A1 (en) 1998-09-28
DK0911033T3 (da) 2004-03-29
US5372808A (en) 1994-12-13
AU683214B2 (en) 1997-11-06
NO943901L (no) 1994-10-14
KR100321467B1 (Direct) 2008-11-13
CN1081909A (zh) 1994-02-16
AU4293493A (en) 1993-11-18
MX9302160A (es) 1994-05-31
EP0911033B2 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
TW265265B (Direct)
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
MY104043A (en) Therapeutic nucleosides.
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
SG52537A1 (en) Methods and compositions for the treatment of cell proliferation disorders
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
MY105855A (en) Therapeutic nucleotides.
MX9704502A (es) Tratamiento de enfermedad autoinmune usando derivados de 2-amino purina.
MY104124A (en) Therapeutic compounds.
NZ514629A (en) PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
MY111746A (en) Therapeutic nucleosides.
GEP19991514B (en) Method for Treatment with Interferon
ZA938915B (en) Treatment of viral infections by conjunctive therapy with acyclovir-like compounds and a 2'-vynyl substituted nucleoside analog
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da